REGENXBIO Inc.

NASDAQ:RGNX

Biotechnology

Healthcare
$7.26 +1.97%

+$0.16 today

Market cap
$480.05M
Beta
1.03
P/E (TTM)
-1.5
EPS (TTM)
-$5.53
52W Low $5.46High $16.19

Volume 0.70M

Average 1.24M

RGNX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

REGENXBIO Inc.NASDAQ: RGNX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation growth accelerates

Q1 FY2026 stock-based compensation of $8.62M rose 0.9% year over year, ahead of the -7.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.9% from the prior quarter. Over 3 fiscal years it compounded at -5.4% a year.

Context

  • Stock-based compensation amounted to 20.3% of revenue in FY2025, down 25.9 pp from a year earlier.
  • Stock-based compensation increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.9% holds above the trailing-twelve-month pace of -7.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$8.62M+2.9% QoQ
Last fiscal yearDec 2025
$34.56M-10.1% YoY
LTMMar 2026
$34.64M-7.4% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.9%——
1 year-10.1%——
3-year CAGR-5.4%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
34.56M USD
Year-over-year change
-10.1%
4-year CAGR
-2.9%

Stock-Based Compensation vs competitors

How RGNX compares with its peers on the latest reported figures

  • RGNX's LTM Mar 2026 stock-based compensation of $34.64M is the 3rd largest of the 10 companies compared; the peer median is $18.36M.
  • Its year-over-year change of -7.4% is the 6th highest of 10, against a peer median of -5.7%.
  • Stock-based compensation amounts to 39.4% of revenue for RGNX, versus a peer median of 48.7%.
RGNX Competitors Peer median
Stock-Based Compensation for RGNX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$47.93M +107.3%-8.3%60.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026$35.22M -20.0%+6.1%—
RGNXREGENXBIO Inc.LTM Mar 2026$34.64M -7.4%-5.4%39.4%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
SLDBSolid Biosciences Inc.LTM Mar 2026$18.73M +52.9%+30.9%—
QUREuniQure N.V.LTM Mar 2026$18.36M -5.7%-19.7%101.5%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$13.6M -8.6%+16.5%37.3%
PGENPrecigen, Inc.LTM Jun 2026$13.14M +42.2%+2.1%15.3%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$11.19M -19.1%+89.6%—
OCGNOcugen, Inc.LTM Mar 2026$9.22M +22.1%-9.9%206.5%
Peer median (excluding RGNX) $18.36M-5.7%+6.1%48.7%

Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income127.84M(280.32M)(263.49M)(227.1M)(193.88M)
Depreciation & Amortization9.56M12.91M17.32M16.22M15.62M
Deferred Income Tax(1.92M)0000
Stock-Based Compensation38.81M40.79M40.27M38.46M34.56M
Change in Working Capital40.22M13.98M(10.89M)5.53M11.78M
Accounts Receivables14.12M4.82M3.94M9.71M(7.66M)
Inventory29.3M0000
Accounts Payables(2.3M)18.79M(2.79M)(292K)(2.28M)
Other Working Capital(899K)(9.64M)(12.03M)(3.88M)21.73M
Other Non-Cash Items4.36M5.16M(1.61M)(6.23M)7.96M
Operating Cash Flow218.88M(207.49M)(218.41M)(173.13M)(123.96M)
Capital Expenditures(84.18M)(30.72M)(9.96M)(2.44M)(2.41M)
Acquisitions (Net)(4.99M)0000
Purchases of Investments(498.14M)(184.88M)(86.56M)(190.14M)(332.63M)
Sales of Investments175.68M203.67M287.47M290.24M319.11M
Other Investing Activities4.99M005.78M62K
Investing Cash Flow(406.64M)(11.93M)190.94M103.45M(15.87M)
Debt Repayment00000
Common Stock Issued218.21M1.74M6.7M131.07M1.01M
Common Stock Repurchased0001.19M0
Dividends Paid00000
Other Financing Activities(22.96M)(30.58M)(41.67M)(39.58M)115.76M
Financing Cash Flow195.25M(28.84M)(34.97M)92.68M116.77M
Effect of Forex Changes00000
Net Change in Cash7.48M(248.26M)(62.43M)23M(23.06M)
Free Cash Flow134.7M(238.21M)(228.37M)(175.56M)(126.38M)

REGENXBIO Inc.

NASDAQ:RGNX

Intrinsic Alpha fair value

Locked

Current Price

$7.26

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.